Radiation therapy after surgery for men with prostate cancer lessens the chance of the cancer coming back, regardless of whether the radiation was administered immediately after surgery or after the cancer recurred, according to a new study in the June 2004 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.
Men with androgen-independent (hormone-refractory) metastatic prostate cancer treated with the breast-cancer drug Taxotere (docetaxel) Injection Concentrate in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy
A study in the American Gastroenterological Association (AGA) journal Gastroenterology has found that men who are treated for prostate cancer with radiation may have almost doubled their risk of developing rectal cancer when compared to men who opted to have surgery.
A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.
Patients with advanced stage prostate cancer who receive radiation therapy immediately after surgery to remove their prostate live longer without their cancer returning than patients who do not receive radiation after surgery, according to a study presented October 17, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.
CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.
Screening younger men and men at risk of prostate cancer can be beneficial in reducing metastatic cancer and deaths and should not be abandoned, states an article published in CMAJ (Canadian Medical Association Journal).